Moreover, PF-04136309 is a CCR2 inhibitor that targets tumor-associated macrophages, and a phase 1b trial revealed that PF-04136309 in combination with FOLFIRINOX chemotherapy decreases the incidence of grade III anemia (8%) in pancreatic cancer compared with FOLFIRINOX alone [153]. Here, CCR2 is linked to anemia.